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Abstract
Background: The nitroreductase/5-(azaridin-1-yl)-2,4-dinitrobenzamide (NTR/CB1954) enzyme/
prodrug system is considered as a promising candidate for anti-cancer strategies by gene-directed
enzyme prodrug therapy (GDEPT) and has recently entered clinical trials. It requires the genetic
modification of tumor cells to express the E. coli enzyme nitroreductase that bioactivates the
prodrug CB1954 to a powerful cytotoxin. This metabolite causes apoptotic cell death by DNA
interstrand crosslinking. Enhancing the enzymatic NTR activity for CB1954 should improve the
therapeutical potential of this enzyme-prodrug combination in cancer gene therapy.
Methods: We performed de novo synthesis of the bacterial nitroreductase gene adapting codon
usage to mammalian preferences. The synthetic gene was investigated for its expression efficacy
and ability to sensitize mammalian cells to CB1954 using western blotting analysis and cytotoxicity
assays.
Results: In our study, we detected cytoplasmic protein aggregates by expressing GFP-tagged NTR
in COS-7 cells, suggesting an impaired translation by divergent codon usage between prokaryotes
and eukaryotes. Therefore, we generated a synthetic variant of the nitroreductase gene, called ntro,
adapted for high-level expression in mammalian cells. A total of 144 silent base substitutions were
made within the bacterial ntr gene to change its codon usage to mammalian preferences. The
codon-optimized ntro either tagged to gfp or c-myc showed higher expression levels in mammalian
cell lines. Furthermore, the ntro rendered several cell lines ten times more sensitive to the prodrug
CB1954 and also resulted in an improved bystander effect.
Conclusion: Our results show that codon optimization overcomes expression limitations of the
bacterial ntr gene in mammalian cells, thereby improving the NTR/CB1954 system at translational
level for cancer gene therapy in humans.
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Background
Cancer is the second most frequent cause of death in
developed countries and a leading cause of death in the
world. Fifty-eight million people died worldwide in 2005
and cancer accounted for 7.6 million (13%) of these
deaths [1]. Twelve million people were newly diagnosed
with cancer last year and the number is prognosed to con-
tinue rising with estimated up to 26 million new cases in
2030 [2]. Thus, novel and effective anti-cancer therapies
are needed to encounter this extending disease.
Conventional cancer treatment involves chemotherapy,
which is able to cure a certain number of cancers, such as
leukemia. However, the chemotherapeutic effect on solid
tumors is often only transient [3]. Chemotherapeutic
drugs interfere with a broad spectrum of intracellular
processes, but most of them target proliferating cells in
general by inhibition of DNA synthesis or DNA damage.
Thus, cancer drugs lack tumor specificity and nearly all
organs become affected after systemic application making
chemotherapy highly dose-limited. However, high drug
concentrations are required to antagonize tumor develop-
ment efficiently and often several chemotherapeutics
need to be combined to circumvent possible drug resist-
ance of cancer cells [3].
Gene-directed enzyme prodrug therapy (GDEPT) is a
promising alternative approach for cancer treatment [4].
The principle of GDEPT involves the genetic modification
of tumor cells to produce enzymes capable of metaboliz-
ing nontoxic prodrugs into potent cytotoxins. This offers
the potential for much higher intratumoral cytotoxin con-
centrations than obtained after systemic application of the
active cytotoxic species itself. Moreover, the specific acti-
vation of chemotherapeutic prodrugs in tumor cells in situ
circumvents the dose-limiting systemic cytotoxicity on
normal tissues, as observed in conventional chemother-
apy. For this purpose, a number of different enzyme/pro-
drug combinations have been established recently [4,5].
The most extensively studied prodrug-activating enzyme
is the Herpes simplex virus type 1 thymidine kinase, which
activates the antiviral agent ganciclovir by phosphoryla-
tion [6]. Another enzyme, the Escherichia coli cytosine
deaminase, catalyzes the deamination of 5-fluorocytosine
to 5-fluorouracil, which is the favored chemotherapeutic
drug in many gastrointestinal malignancies [4,7]. The
active species of both enzyme/prodrug systems are nucle-
otide analogues that interfere with DNA synthesis causing
chain termination and cell death exclusively in proliferat-
ing cells. These antimetabolite-producing systems have
been successfully used in growing cell cultures and cancer
tumor models [4,7]. However, their clinical applicability
in gene therapy has been challenged in phase I and II trials
by the fact that in human tumors non-dividing cells are
much more abundant than proliferating cells, rendering
most of the tumor cells insensitive to the prodrug [8].
Thus, alternative enzyme/prodrug combinations, which
do not discriminate between dividing and non-dividing
cells, for example by generating alkylating agents, are
more suitable for gene therapy approaches.
In 1969 Cobb et al. reported that rat Walker 256 carci-
noma cells are exceptionally sensitive to the weak mono-
functional alkylating agent 5-(azaridin-1-yl)-2,4-
dinitrobenzamide (CB1954) in comparison with Chinese
hamster V79 cells [9]. This cytotoxicity was subsequently
found to depend on the enzyme DT diaphorase in Walker
tumor cells, which catalyzes the aerobic reduction of the
4-nitro group of CB1954 in the presence of NADH or
NADPH [10]. The resulting 4-hydroxylamine derivative
undergoes a further non-enzymatic reduction with cellu-
lar thioesters to become a potent DNA crosslinking agent
[10]. As this DNA damage is poorly repaired, CB1954
treatment results in cell death via apoptosis in a p53-inde-
pendent manner [4,11,12]. However, human cell lines are
less sensitive to CB1954 due to a far lower activity of
human DT diaphorase compared with the rat enzyme
[10]. This fact, together with the identification of a bacte-
rial nitroreductase (NTR) in E. coli, which bioactivates
CB1954 about 60 times more efficiently than the Walker
DT diaphorase, then increased the potential for applica-
tion of CB1954 as an anti-tumor agent in humans [10].
Consistently, the specific cell ablation in different tissues,
for example in mammary gland and the brain, has proven
the potent applicability of the NTR/CB1954 system in
transgenic animal models [11,13-15]. Nevertheless, high
prodrug dosages are required to obtain the desired cell
ablation resulting in side effects, such as considerable
weight loss and testis degeneration (own observations).
Recent investigations have focused on the optimization of
the NTR/CB1954 system by site-directed mutagenesis of
the enzymes catalytic core [16,17]. However, the prodrug-
metabolizing activity depends also on the amount of
functional protein in the cell. The expression of prokaryo-
tic genes in eukaryotes is often hampered by differential
codon usage, whose pattern is not conserved in taxonom-
ically distant species and specific biases exist [18,19]. The
bacterial codon usage was shown to affect recombinant
protein translation in mammals [20,21]. Therefore,
codon optimization has been applied to improve the
expression for a variety of bacterial genes in eukaryotes
[20,21].
Here we show that expression of a gfp-tagged E. coli ntr
gene (gntr) in mammalian cells is accompanied by aggre-
gation of the recombinant fusion protein. A synthetic ver-
sion, termed gntro, with silent mutations that adapt codonBMC Cancer 2009, 9:301 http://www.biomedcentral.com/1471-2407/9/301
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usage to mouse preferences showed higher protein levels
and largely enhanced sensitivity to the prodrug CB1954
after expression in different mammalian cell lines.
Methods
Plasmids (constructs)
The nitroreductase gene (nfsB, ntr) was amplified from E.
coli DH5α genomic DNA by PCR with the primers 5'-
GTCTTTATGGATATCATTTCTGTCG-3' (forward) and 5'-
AGAGAGAATTACACTTCGGTTAAGG-3' (reverse). The
obtained 654 bp amplicon was subcloned into pGEM®-T
easy (Promega) and confirmed by sequencing. The codon-
optimized ntro gene (Figure 1) was custom-synthesized by
GeneScript (NJ, USA) and provided into the pUC57 sub-
cloning vector. Codon usage tables were obtained from
http://www.kazusa.or.jp[22]. To express nitroreductase
with a N-terminal GFP-tag both genes were cut out with
EcoR I from the respective source vectors and cloned into
pEGFP-C1 (Clontech) using EcoR I restriction sites. The
obtained constructs pGNTR and pGNTRo slightly differed
in linker sequence (5 of 17 amino acids) and were used
for all cell culture experiments. Amino- and carboxytermi-
nally c-myc-tagged ntr constructs were generated by PCR-
amplification from pGEM-NTR and pUC57-NTRo using
either the primer pairs 5'-GGATCCATGGATATCATTTCT-
GTCG-3'/5'-AAGCTTTTACACTTCGGTTAAGGTG-3'
(pMycNTR) and 5'-GGATCCATGGACATCAT-
CAGCGTGG-3'/5'-AAGCTTTCACACC TCGGTCAGGG-3'
(pMycNTRo) or 5'-GGATCCGCCGCCATGGATATCATT-
TCTG-3'/5'-AAGCTTCACTTCGGTTAAGGTGATGTTTTG-
3' (pNTR-myc) and 5'-GGATCCGCCGC CATGGACAT-
CATCAGCG-3'/5'-AAGCTTCACCTCGGTCAGGGTGAT-
GTTC-3' (pNTRo-myc), respectively. The primers
provided 5'-BamH I and 3'-Hind III restriction sites for
subsequent cloning. All amplicons were subcloned into
pGEM®-T easy and confirmed by sequencing. To express
N-terminally-tagged NTR, the amplicons were cloned into
pCMV-Tag3B (Stratagene) using BamH I and Hind III
restriction sites. For the expression of the C-terminally-
tagged NTR, the corresponding amplicons were cloned
into pcDNA3.1/myc-His (-) A (Invitrogen), using the
same strategy.
Cell lines and culture conditions
Green monkey kidney (COS-7), human embryonic kid-
ney (HEK-293), human neuroblastoma (SH-SY5Y),
human small cell lung carcinoma (SHP-77), human oste-
osarcoma (U-2 OS), mouse fibroblast (3T3-L1), and
mouse mastocytoma (P815) cells were maintained under
standard conditions at 37°C and 5% CO2 in DMEM or
RPMI (SHP-77 and P815) supplemented with 10% fetal
bovine serum and antibiotics. COS-7 cells were trans-
fected with the DEAE-dextran pretreatment method. Tran-
siently transfected COS-7 cells were either used for
cytotoxicity assays 24 hours after transfection by cultivat-
ing them with different CB1954 concentrations or for
Western blot analysis at indicated time points. To estab-
lish stable cell lines, cells were transfected with DreamFect
(OZ Biosciences) according to the manufacturer's instruc-
tions and selected in presence of 500 μg/ml G418 for 2
weeks. After selection, G418-resistent cells were pooled
and FACS-sorted to purity using GFP as a fluorescence
marker.
MTT assay
Stable cells were seeded in quadruplicate on 24-well
plates (2*105 cells/well) in DMEM without Phenol Red
supplemented with different CB1954 concentrations.
MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) was added to each well after 48
hours to a final concentration of 0.5 mg/ml and cells were
further incubated for 2 hours. Cells were detached,
washed with PBS and suspended in 1 ml MTT stop solu-
tion (0.04 M HCl in isopropanol) to solubilize formazan
crystals. After centrifugation supernatants were transferred
in duplicate to a 96-well plate and extinctions were meas-
ured at 570 nm.
Cell counting
Transiently transfected COS-7 cells were seeded in tripli-
cate on a 96-well plate with the indicated concentrations
of CB1954. The surviving green cells were counted after 48
hours of treatment within a field of view at 10× magnifi-
cation using an Axiovert 40 microscope (Zeiss). A total of
six randomly chosen fields were counted per experimental
condition.
Immunoblot analysis
After washing with PBS, cells were incubated on ice with
RIPA lysis buffer (50 mM Tris-HCl pH 8.0; 150 mM NaCl;
1% NP-40; 0.5% DOC; 0.1% SDS) supplemented with
protease inhibitors (Roche) for 10 min. Soluble fractions
of cellular lysates were obtained by centrifugation at
20000 × g and 4°C for 5 min. Protein concentrations were
determined using Bradford reagent (Sigma). Cellular
lysates were separated by 12% SDS-PAGE and transferred
to nitrocellulose (Amersham). Membranes were blocked
with 3% BSA in phosphate-buffered saline (PBS) contain-
ing 0.1% Tween-20 and then probed sequentially with
monoclonal mouse anti-GFP (1:2000, Cat. No. 1814460,
Roche) or c-myc (1:500, sc-40, Santa Cruz Biotechnology)
antibodies and the corresponding HRP-conjugated goat
anti-mouse antibody (1:60000, A0168, Sigma). Loading
of equal amounts of protein was confirmed by reprobing
with polyclonal goat anti-actin (1:5000, sc-1616, Santa
Cruz Biotechnology) and donkey anti-goat-HRP antibod-
ies (1:60000, sc-2020, Santa Cruz Biotechnology). Immu-
noreactive bands were visualized with ECL PLUS (Perkin-
Elmer).BMC Cancer 2009, 9:301 http://www.biomedcentral.com/1471-2407/9/301
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Nucleotide sequence of nitroreductase cDNA and the deduced amino acid sequence Figure 1
Nucleotide sequence of nitroreductase cDNA and the deduced amino acid sequence. The point mutations of ntro 
are shown below the substituted nucleotides of ntr. The corresponding amino acid is indicated above each codon.BMC Cancer 2009, 9:301 http://www.biomedcentral.com/1471-2407/9/301
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Fluorescence microscopy
Transiently transfected COS-7 cells were seeded on glass
cover slips and cultivated in presence of various CB1954
concentrations for 24 hours. Cells were then fixed with
3.7% formaldehyde in PBS for 10 min. Genomic DNA
was stained with DAPI (1 μg/ml in PBS), washed with PBS
and mounted in Mowiol. Specimens were analyzed with
10× and 63× planapochromat objectives on an Axiovert
200 M microscope (Zeiss) equipped with epifluorescence
optics.
Statistical analysis
All data are presented as means ± SEM and two-tailed
unpaired Student's t-test was used to compare data sets.
Values of p < 0.05 were considered as statistically signifi-
cant.
Results
Expression of gntr in COS-7 cells results in protein 
aggregation
To test the efficacy of bacterial ntr  gene expression in
mammalian cell lines, we generated a gfp/ntr fusion con-
struct (pGNTR) that facilitates the detection of NTR pro-
tein expression either by fluorescence microscopy or
immunodetection (Figure 2A). Interestingly, we could
detect perinuclear protein aggregates in the cytoplasm of
approximately 10% of the pGNTR-transfected COS-7 cells
48 hours after transfection (Figure 2B). Thus, the question
arose whether the divergent codon usage of prokaryotes
and eukaryotes was responsible for the aggregates as
approximately 60% of the bacterial ntr codons are under-
represented in mammalian genomes (e.g. Mus musculus;
Figure 2A and Additional file 1) [22].
To test our hypothesis, we designed a synthetic version of
the ntr gene, in which the rare codons for mammalian
expression of the wild type E. coli gene were replaced by
codons preferentially used in mammalian genomes (Fig-
ure 1). A total of 144 base substitutions in 124 codons
were introduced without changing its amino acid
sequence. The resulting codon-optimized ntr  version
(ntro) was fused to gfp and the corresponding pGNTRo
construct (Figure 2A) was used to transfect COS-7 cells to
directly compare gntro expression with gntr. Indeed the
cytoplasmic aggregates evident for gntr-expressing cells
could no longer be detected in cells expressing gntro (Fig-
ure 2B). Furthermore, the GNTR expression was remarka-
bly improved after codon usage optimization to ~3-fold
higher protein levels 24 hours after transfection (Figures
3A and 3B). The elevated gntro  expression was stable
throughout 48 to 72 hours with an average expression
level 2-fold higher than of the wild type gene. In order to
exclude any artefactual expression difference caused by
the aminoterminal GFP-tag, amino- and carboxyterminal
c-myc constructs were generated and tested by immunob-
lotting (Figures 3C and 3D). All codon-optimized expres-
sion constructs proved to lead to higher NTR levels as
compared with the wild type cDNAs, using several inde-
pendent batches of plasmid DNA.
Codon optimization increases the sensitivity to CB1954
To test the enzymatic activity of GFP-tagged nitroreduct-
ase, we performed cytotoxicity assays to determine the
sensitivity of both GNTR-expressing cell lines to the prod-
rug CB1954 (Figure 4A). Transfected COS-7 cells were
The expression of the bacterial nitroreductase gene in COS- 7 cells results in protein aggregation Figure 2
The expression of the bacterial nitroreductase gene 
in COS-7 cells results in protein aggregation. (A) Sche-
matic representation of the coding regions concerning 
GNTR expression in pGNTR and pGNTRo constructs, 
respectively. The wild type ntr gene and the codon-optimized 
ntro gene were N-terminally fused to gfp providing a marker 
for NTR expression. The bacterial ntr sequence contains sev-
eral critical codons (red bars) for the expression in mamma-
lian cells. In pGNTRo all critical ntr codons have been 
adapted to the preferred codon usage in mouse to ensure 
optimal expression in mammalian cells. (B) Perinuclear struc-
tures (white arrowheads) are present in approximately 10% 
of pGNTR-transfected COS-7 cells, indicating protein aggre-
gation 48 hours after transfection. Protein aggregation was 
not present in gntro-expressing cells after codon optimiza-
tion. GFP-labeled nitroreductase (green) and DAPI-stained 
DNA (blue) are shown in overlay. Scale bar = 50 μm.BMC Cancer 2009, 9:301 http://www.biomedcentral.com/1471-2407/9/301
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treated with different concentrations of CB1954 for 24
hours. Fluorescence microscopy revealed efficient abla-
tion of gntr-expressing cells by CB1954 at 50 μM. How-
ever, similar results were observed already at the 10 times
lower prodrug concentration of 5 μM in cells expressing
the optimized gntro gene. Control cells expressing gfp were
not affected by 5 μM CB1954, but interestingly an unspe-
cific reduction of cell proliferation was observed at 50 μM.
To identify the lowest effective concentration, transfected
COS-7 cells were exposed to CB1954 in the range of 0 to
150  μM (Figure 4B). Cells expressing gntro  already
responded to 1 μM CB1954 with only 41% of living cells
48 hours after prodrug treatment. In contrast, no effect
could be detected in gntr-expressing cells and significant
signs of apoptosis became first evident at 10 μM and 25
μM CB1954, where 39% and 67% of the cells were killed,
respectively. However, at these concentrations only about
5% of the gntro-expressing cells survived. Comparable
ablation for gntr-expressing cells were obtained only at
100 μM and 150 μM CB1954, but the number of control
cells was also decreased at these concentrations, most
likely due to inhibition of cell proliferation as revealed by
microscopic analysis (data not shown).
Codon optimization overcomes tissue-specific codon 
usage limitations
COS-7 cells represent an artificial system for ectopic gene
expression [23]. Thus, stable cell lines from diverse tissues
were required to confirm the improvement of the NTR/
CB1954 system by codon usage optimization under more
native conditions. Therefore, we generated human embry-
onic kidney (HEK-293), human neuroblastoma (SH-
SY5Y), human small cell lung carcinoma (SHP-77),
human osteosarcoma (U-2 OS), mouse fibroblast (3T3-
L1), and mastocytoma (P815) cell lines stably expressing
gntr, gntro and gfp (control) and treated them with differ-
ent concentrations of CB1954 (Figure 5 and Additional
file 2).
Remarkable differences in survival rates were detected in a
concentration dependent manner after 48 hours of treat-
The nitroreductase expression in COS-7 cells is improved by codon usage optimization Figure 3
The nitroreductase expression in COS-7 cells is improved by codon usage optimization. (A) At the indicated time 
points cleared cellular lysates (20 μg) of pGNTR and pGNTRo-transfected cells were analyzed by immunoblotting using anti-
GFP and anti-actin (loading control) antibodies. (B) Densitometric quantification of GNTR protein levels normalized to actin. 
Combined data of two independent experiments are represented as means ± SEM. *: p < 0.05; n = 2. (C, D) Consistently, the 
amino- (C) and carboxyterminally c-myc-tagged (D) ntro showed similarly improved expression levels as compared with the 
corresponding ntr constructs.BMC Cancer 2009, 9:301 http://www.biomedcentral.com/1471-2407/9/301
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ment (Figure 5A, B and 5C). All gntro-expressing cell lines
showed a dramatic decrease in cell number already at 5
μM CB1954 with only 17%, 30% and 16% of cells still
alive as compared with control cells, respectively. Almost
no cells survived at 50 μM CB1954. These results were in
line with the data obtained from COS-7 cells transiently
transfected with gntro (Figure 4B). CB1954 also decreased
the cell number of gntr-expressing HEK-293 and SHP-77
cells dose-dependently, but the sensitivity was clearly
lower at all concentrations compared with gntro-express-
ing cells. Indeed, 58% and 64% of gntr-expressing HEK-
293 and SHP-77 cells were still alive at 5 μM and higher
ablation rate of 72% and 94% were only reached at 100
μM, respectively (Figure 5A and 5C). These results were
consistent with other stable human (U-2 OS) and mouse
(P815, 3T3-L1) cell lines tested (Additional file 2).
Surprisingly,  gntr  expression in SH-SY5Y cells had no
effect on their sensitivity to CB1954 (Figure 5B). The
observed decrease in cell number of approximately 40%
in these cells was not different from gfp-expressing control
cells and was most likely caused by a CB1954-mediated
Codon optimization increases the cytotoxicity of the NTR/CB1954 system in transiently transfected cells Figure 4
Codon optimization increases the cytotoxicity of the NTR/CB1954 system in transiently transfected cells. (A) 
COS-7 cells, transfected with pGNTR, pGNTRo or pEGFP-C1 (control) were cultivated in presence of increasing CB1954 
concentrations. The survival of transfected cells (green) was analyzed by fluorescence microscopy 24 hours after CB1954 
treatment. The DNA was stained with DAPI (blue). Scale bar = 100 μm. (B) The prodrug-mediated cell death was quantified by 
counting GNTR-expressing cells (green) 48 hours after treatment with CB1954. Cells expressing gntro were nearly fully 
depleted at concentrations below 25 μM, whereas a similar effect in gntr-expressing cells was observed only at CB1954 con-
centrations higher than 100 μM. Shown is one representative experiment out of two repetitions. *: p < 0.05; n = 3.BMC Cancer 2009, 9:301 http://www.biomedcentral.com/1471-2407/9/301
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inhibition of cell proliferation, as revealed by microscopic
analysis. These results were consistent with another neu-
ronal cell line (NG-108) tested (data not shown), most
likely due to differential tissue-specific codon usage
[24,25].
The presence of full-length GNTR protein was analyzed in
all cell lines through immunoblotting of whole cellular
lysates using an anti-GFP antibody (Figure 5D). The
expression of gntr was less efficient to that of gntro in all
three cell lines and correlates with the decreased sensitiv-
ity of these cells to CB1954 (Figure 5A, 5B and 5C).
Codon optimization improves bystander effect
The bystander effect is an important aspect of tumor abla-
tion using GDEPT, which is often desired to overcome
limitations of gene delivery to allow effective tumor
regression with a low number of suicide gene-expressing
cells [26-28]. In order to assess for this effect, various
ratios of stably transfected ntr-positive (ntr+) and wild
type HEK-293 cells were mixed and kept at the indicated
Codon optimization increases the sensitivity of stable human cell lines to the prodrug CB1954 Figure 5
Codon optimization increases the sensitivity of stable human cell lines to the prodrug CB1954. (A) HEK-293, (B) 
SH-SY5Y and (C) SHP-77 cells stably transfected with pGNTR, pGNTRo or pEGFP-C1 (control). MTT assays were performed 
to determine relative cell viability after 48 hours of cultivation in presence of different CB1954 concentrations. One represent-
ative experiment out of three is shown. *: p < 0.05; n = 4. (D) The expression of GNTR was confirmed by immunodetection 
using anti-GFP and anti-actin (loading control) antibodies. Amount of lysate loaded to each lane: pEGFP-C1 (3 μg), pGNTR (20 
μg) and pGNTRo (20 μg).BMC Cancer 2009, 9:301 http://www.biomedcentral.com/1471-2407/9/301
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concentrations of CB1954 (Figure 6). Cell survival and
viability was then quantified using a MTT assay after 48
hours of treatment. At 5% ntr+ cells, only gntro-expressing
cells showed a detectable bystander effect, even at a
CB1954 concentration of 5 μM (Figure 6A). A similar
effect was detected for gntr-expressing cells only at 25%
ntr+ cells and 25 μM prodrug (Figure 6A). SHP-77 cells,
although responding only at 25% ntr+ and 25 μM (gntro),
also showed a bystander effect, while gntr-expressing cells
did not (Figure 6B).
Discussion
Chemotherapy as one pillar of conventional cancer treat-
ment is associated with severe side effects. GDEPT with
prodrug-activating enzymes is a very promising approach
for anti-cancer treatment, which provides the opportunity
to generate high local cytotoxin concentrations in tumor
cells without causing systemic cytotoxicity. Among the
systems described so far, alkylating agent-producing sys-
tems are believed to be the best candidates for GDEPT
approaches in humans because of their independence
from cell proliferation [4]. This is particularly important
because the number of proliferating cells in human solid
tumors is estimated being only about 6% [8]. Especially
the NTR/CB1954 system is considered promising, since
CB1954-mediated apoptosis is independent from the
tumor suppressor gene p53, which is inactive in more than
50% of all human cancers [12,29]. For this reason we
decided to analyze the expression of bacterial NTR in
mammalian cells in order to assess for optimal transla-
tional efficacy.
The therapeutical benefits of such enzyme/prodrug sys-
tems depend on the cytotoxin-producing activity, which
can be obtained in tumor cells. Many efforts have been
undertaken to improve the catalytic activity of NTR, for
instance by site-directed mutagenesis of the catalytic core
[16,17]. A F124K mutant was described, which is 5-fold
more potent in sensitizing SKOV3 ovarian carcinoma cells
to CB1954 [16]. More recently, a number of new "turbo-
NTR" variants were identified by library screening [17].
The most effective T41Q/N71S/F124T-NTR triple mutant
showed sensitization of SKOV3 carcinoma cells already at
40- to 80-fold lower CB1954 concentrations than
required for the wild type NTR [17]. However, the sensi-
tivity to the prodrug remains limited by the amount of
functional NTR protein in the cell.
Codon usage has been shown to impair expression of bac-
terial genes in eukaryotes [20,21], most probably due to
depletion of tRNAs for rare codons. This can delay trans-
lational processing and affect cotranslational protein fold-
ing of the nascent protein chain. Accordingly, the
expression of the bacterial gntr  gene in COS-7 cells
resulted in the formation of cytoplasmic protein aggre-
gates (Figure 2B). Adaptation of the E. coli-specific codon
usage for GNTR expression in mammals abolished pro-
tein aggregation (Figure 2B) and enabled generation of
high protein levels in COS-7 cells (Figure 3A), as shown
for other bacterial genes [20,21]. As GFP can form dimers
at high concentrations, and NTR is also dimeric, the
observed aggregation could be also mediated by the GFP
portion of the GNTR fusion protein. However, our results
rather point to a translational problem, because the much
higher gntro expression did not lead to such aggregates
(Figure 2B).
High dosages of CB1954 caused mild side effects in trans-
genic mice, for example temporary weight loss of ~10%
[13,15,30], most likely due to effects on the intestinal
flora (presence of E. coli bacteria in the intestinal tract),
but also more severe effects, like testis degeneration
(unpublished observations). Chung-Faye et al. reported
no significant toxicity of CB1954 up to 24 mg/m2 in
humans, whereas dose-limiting toxicities were seen at
37.5 mg/m2, causing diarrhea and hepatic toxicity in
phase I clinical trials [31]. In respect of these side effects,
the more efficient expression of the synthetic ntro gene
used in this study allows application of lower CB1954
concentrations in vitro (Figure 4 and 5). However, the high
efficacy of ntro has to be determined in vivo in follow-up
studies, where lower prodrug concentrations should limit
the negative side effects observed in mice.
Our results clearly show the improvement of the NTR/
CB1954 enzyme/prodrug system by using a mammalian-
ized version of ntr. Most mammals, including humans
and mouse, have a very similar codon usage [22]. Thus,
our optimized ntro  gene should also be suitable for
human applications. This was demonstrated by the
expression of gntro in several human cell lines (HEK-293,
SHP-77, U-2 OS), which results in higher expression and
increased sensitization of these cells to CB1954 compared
with gntr-expressing cells (Figure 5 and Additional file 2).
Moreover, the codon adaptation leads to an improved
bystander effect (Figure 6). Several in vitro and in vivo stud-
ies have proven a potent bystander effect for the NTR/
CB1954 system [26-28], which we also detected in gntr-
expressing COS-7 and HEK-293 cells (Figures 4A and 6A).
This is an important aspect of tumor ablation using
GDEPT, which is often desired to overcome limitations of
gene delivery and low numbers of suicide gene-expressing
cells, suggesting higher tumor regression efficacy of the
optimized NTR/CB1954 system.
In spite of the previous reports successfully using the NTR/
CB1954 system in various applications in the brain
[13,14,30], we noticed expression problems of gntr  in
neuronal cell lines resulting in an inefficient response toBMC Cancer 2009, 9:301 http://www.biomedcentral.com/1471-2407/9/301
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Codon optimization improves the bystander effect of the NTR/CB1954 system Figure 6
Codon optimization improves the bystander effect of the NTR/CB1954 system. (A) At 5% NTR-positive (ntr+) 
HEK-293 cells, only pGNTRo led to a detectable bystander effect, starting at a CB1954 concentration of 5 μM 48 hours after 
treatment. The effect of pGNTR became detectable at 25% ntr+ cells and 25 μM prodrug. (B) SHP-77 expressing gntro showed 
a significant bystander effect only at 25% ntr+ cells and 25 μM, while gntr-expressing cells did not. (A, B) The 100% ntr+ control 
experiments consistently reproduced the results obtained in Figure 5A and C. The data are normalized to the corresponding 
CB1954-untreated cell pools. Shown is one representative experiment out of two repetitions. *: p < 0.05; n = 3.BMC Cancer 2009, 9:301 http://www.biomedcentral.com/1471-2407/9/301
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the prodrug CB1954 (Figure 5B). SH-SY5Y cells stably
expressing gntr were growth-inhibited but not ablated by
CB1954 in contrast to cells expressing the optimized gntro
gene. Interestingly, HEK-293, SHP-77, U-2 OS, 3T3-L1
and P815 cells either expressing gntr or gntro were effi-
ciently ablated by the prodrug (Figure 5A and 5C). Plotkin
et al. (2004) reported differences in synonymous codon
usage between genes selectively expressed in six adult
human tissues, suggesting that codon-mediated transla-
tional control may play an important role in the differen-
tiation and regulation of tissue-specific genes in humans
[24]. Furthermore, Dittmar et al. reported that isoaccept-
ing tRNAs are differentially expressed in a study spanning
eight human tissues [25]. Hence, these findings could
explain the differences between non-neuronal and neuro-
nal cells used in our study.
For an efficient application in human cancer treatment
GDEPT requires the specific delivery of the prodrug-acti-
vating genes to tumor cells, a problem, which has not
been solved yet. Many efforts have been undertaken to
develop adenoviruses and retroviruses as gene delivery
vehicles. Prolonged survival times or even complete cure
were observed in murine xenograft models of human can-
cers [27,32,33]. Furthermore, adenoviral gene delivery of
ntr was tested in first clinical trials in patients with liver
tumors showing the feasibility and tolerance of that
approach [34].
Conclusion
Our data provide evidence that the NTR/CB1954 system
can be efficiently improved at the translational level by
codon usage optimization, thereby increasing its potential
as GDEPT for human cancer. Moreover, codon usage opti-
mization should be also of relevance for other enzyme/
prodrug systems. Finally, the codon-optimized ntro devel-
oped in this study should be also of value for the investi-
gation of cell functions by conditional targeted cell
ablation in transgenic animals.
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